Bioatla

Bioatla EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Bioatla (BCAB) as of Nov 18, 2026 is -428.88 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -141.05 % — a change of 204.05% (lower).

EBIT/Assets

-428.88 %

YoY

204.05%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Bioatla is 2025 -428.88 % . Operating Income to Assets Ratio (EBIT/Assets) of Bioatla was 2024 -141.05 % . It decreases by 204.05% lower compared to the previous year.

The Bioatla EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
-169.74 USD
Jan 1, 2019
-303.70 USD
Jan 1, 2020
-14.11 USD
Jan 1, 2021
-37.91 USD
Jan 1, 2022
-47.91 USD
Jan 1, 2023
-108.38 USD
Jan 1, 2024
-141.05 USD
Jan 1, 2025
-428.88 USD
The Bioatla EBIT/Assets history
YEAREBIT/AssetsYoY
-428.88 %+204.05%
-141.05 %+30.15%
-108.38 %+126.24%
-47.91 %+26.38%
-37.91 %+168.62%
-14.11 %-95.35%
-303.70 %+78.92%
-169.74 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bioatla Stock analysis

What does Bioatla do? BioAtla develops antibody-based therapeutics for solid tumor cancer, focusing on conditionally active biologics (CAB) antibody-drug conjugates (ADCs). Its lead product BA3011 targets AXL, a protein kinase receptor, while BA3021 targets ROR2, a receptor tyrosine kinase. BA3071 is a CAB anti-CTLA-4 antibody for multiple solid tumors including renal cell carcinoma and melanoma, and BA3182 uses Dual-CAB technology for adenocarcinoma treatment. The company generates revenue through the development and commercialization of these product candidates, targeting oncology treatment markets with specific therapeutic approaches. BioAtla's product pipeline includes BA3011, BA3021, BA3071, and BA3182, each addressing distinct cancer targets. The company focuses on developing novel therapeutics rather than selling existing products, with BA3011 as its lead candidate. Revenue is expected from future partnerships, licensing agreements, or eventual product sales once clinical development progresses to later stages. The company's business model centers on advancing its pipeline through clinical trials, with potential revenue streams from biopharmaceutical partnerships and product launches. BA3071 targets multiple solid tumor indications, including NSCLC and hepatocellular carcinoma, while BA3182 is designed for advanced adenocarcinoma. BioAtla's focus on CAB technology differentiates its approach in the oncology space. Bioatla is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bioatla stock

Operating Income to Assets Ratio (EBIT/Assets) of Bioatla is -428.88 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of Bioatla changed from -141.05 % to -428.88 %, representing a 204.05% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Bioatla since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Bioatla with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Bioatla

All Key Metrics — Bioatla